Alcon Company Profile
What is the competitive landscape for ALCON
ALCON has fifty-eight approved drugs.
There are forty-six US patents protecting ALCON drugs. There is one tentative approval on ALCON drugs.
Summary for Alcon
| US Patents: | 46 |
| Tradenames: | 49 |
| Ingredients: | 41 |
| NDAs: | 58 |
| Patent Litigation for Alcon: | See patent lawsuits for Alcon |
| PTAB Cases with Alcon as patent owner: | See PTAB cases with Alcon as patent owner |
Drugs and US Patents for Alcon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | 9,415,043 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | 9,393,213 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alcon Labs | TETRACAINE HYDROCHLORIDE | tetracaine hydrochloride | SOLUTION;OPHTHALMIC | 208135-001 | Feb 29, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alcon
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | 11,021,456 | ⤷ Start Trial |
| Alcon | BSS PLUS | calcium chloride; dextrose; glutathione disulfide; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate | SOLUTION;IRRIGATION | 018469-001 | Approved Prior to Jan 1, 1982 | 4,550,022 | ⤷ Start Trial |
| Alcon Labs Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | 10,532,993 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALCON drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 0.03% | ➤ Subscribe | 2004-12-23 |
| ➤ Subscribe | Ophthalmic Solution | 0.00% | ➤ Subscribe | 2008-11-28 |
International Patents for Alcon Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2023030072 | ⤷ Start Trial |
| Spain | 2776199 | ⤷ Start Trial |
| Slovenia | 2722035 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alcon Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | 1990003-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/17/1179, 2017-07-21; PRV HAR I BESLUT DEN 16 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 1990003-4 2190008-9 |
| 1280520 | 92678 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725 |
| 0933372 | PA2008006,C0933372 | Lithuania | ⤷ Start Trial | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
